CPT 0141U: ePlex® BCID Gram-Positive Panel for Rapid Blood Culture Pathogen Detection - OpenPayer

Beta

OpenPayer Beta

Summary & Overview

CPT 0141U: ePlex® BCID Gram-Positive Panel for Rapid Blood Culture Pathogen Detection

CPT code 0141U identifies a proprietary molecular diagnostic assay — the ePlex® BCID gram–positive panel from GenMark Diagnostics — used for rapid detection of multiple gram-positive bacterial targets, select resistance genes, and pan-targets for gram-negative bacteria and Candida from positive blood cultures. As a PLA code, 0141U applies only to this specific commercial test and matters nationally because rapid, targeted pathogen identification can influence antimicrobial management and hospital infection care pathways. Coverage and payment for PLA tests are closely watched by national payers and Medicare due to clinical impact and cost considerations. Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical role of the assay, how CPT code 0141U is used in billing, typical sites of service where the test is performed, and what to expect from national payer engagement. The publication also outlines benchmarking topics and policy considerations relevant to proprietary laboratory analyses, including coding specificity, payer coverage patterns, and implications for laboratory workflow and hospital diagnostic protocols. Data not available in the input for specific payer policies, reimbursement rates, associated taxonomies, and ICD-10 pairings are noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0141UCPTProprietary Laboratory AnalysesMolecular DiagnosticsBlood CultureGram-Positive PanelInfectious DiseaseLaboratory Medicine

Billing Code Overview

CPT code 0141U is a Proprietary Laboratory Analyses (PLA) code for the ePlex® BCID gram–positive panel (GenMark Diagnostics Inc.). The test uses an automated amplified probe technique for rapid detection of 20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, and 1 pan Candida target from positive blood cultures.

Service type: Proprietary molecular diagnostic laboratory test for pathogen and resistance gene detection from positive blood culture specimens
Typical site of service: Hospital or independent clinical laboratory processing positive blood cultures for rapid identification of bloodstream infection pathogens and select resistance markers

Clinical & Coding Specifications

Clinical Context

A patient presents to the emergency department with fever, hypotension, and suspected sepsis after a recent central line placement. Blood cultures are obtained and one set flags positive for gram-positive organisms on the automated blood culture instrument. The clinical team requests rapid organism identification and resistance marker detection to guide early antimicrobial therapy. The laboratory receives the positive blood culture bottle and performs the ePlex® BCID gram–positive panel (0141U) using an automated amplified probe platform. Results return within hours, reporting identification of gram-positive bacterial targets and relevant resistance genes (e.g., mecA). The laboratory issues the report to the ordering clinician, who uses the findings to narrow or escalate empiric antibiotics, adjust infection control measures, and inform whether additional testing (e.g., susceptibility testing, molecular testing for gram-negative or fungal targets) is required. Typical sites of service include the hospital clinical microbiology laboratory supporting inpatient care, emergency department, and intensive care unit workflows.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the professional interpretation component of the test if applicable and separable.

Taxonomy Code	Specialty	Notes
`207RG0100X`	Infectious Disease Physician	Oversees clinical interpretation and antimicrobial stewardship decisions based on results.
`207L00000X`	Microbiology Laboratory Director	Clinical laboratory physician responsible for test validation and result oversight.
`363LP0200X`	Clinical Laboratory Technologist/Technician	Performs the test and reports results in the microbiology lab.
`207K00000X`	Internal Medicine Hospitalist	Orders the test for inpatient sepsis and acts on results for antimicrobial management.
`207U00000X`	Emergency Medicine Physician	Orders rapid testing when sepsis is suspected on presentation.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`A41.9`	Sepsis, unspecified organism	Common indication for rapid identification from positive blood cultures to guide therapy.
`A41.51`	Sepsis due to Methicillin resistant Staphylococcus aureus (MRSA)	Rapid detection of MRSA and mecA gene by the panel directly impacts antibiotic selection.
`R65.20`	Severe sepsis without septic shock	Used when organ dysfunction accompanies infection; rapid ID informs urgent management.
`A41.02`	Sepsis due to Methicillin susceptible Staphylococcus aureus (MSSA)	Differentiation between MSSA and MRSA guides de-escalation to beta-lactam therapy if MSSA is identified.
`B37.7`	Candidemia	The panel includes a pan-Candida target to detect Candida species in bloodstream infections.
`T80.211A`	Sepsis due to central venous catheter, initial encounter	Central line-associated bloodstream infections commonly prompt rapid diagnostic testing with this panel.
`I10`	Essential (primary) hypertension	Common comorbidity in inpatients; may appear on the problem list of patients undergoing testing.
`Z51.81`	Encounter for therapeutic drug monitoring	May be listed in courses of care where antimicrobial levels are monitored in severe infections and the panel results influence therapy.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`87040`	Culture, bacterial; blood, aerobic	Performed when blood cultures are initially set up; positive cultures trigger use of `0141U` for rapid ID.
`87070`	Culture, bacterial; blood, anaerobic	Paired with aerobic cultures; provides growth data that may prompt `0141U` testing if gram-positive growth is present.
`87471`	Infectious agent detection by nucleic acid (e.g., PCR), direct probe technique; qualitative, multiple organisms	Represents alternative molecular identification tests that may be ordered when panel testing is not available.
`87181`	Susceptibility testing by disk diffusion method	Performed after organism identification to determine antimicrobial susceptibilities guiding definitive therapy.
`87880`	Infectious agent antigen detection by immunoassay, multiple-step technique	Represents other rapid tests (e.g., for Candida) that might be ordered alongside or prior to molecular panel testing.
`0141U`	ePlex® BCID gram–positive panel, GenMark Diagnostics Inc.	Proprietary rapid molecular panel used for identification of multiple gram-positive targets and resistance genes from positive blood cultures; central to early organism ID in the workflow.